Hepatitis C Treatment: Price, Profits, and Barriers to Access
The World Health Organization estimates that as many as 185 million people, or 3 percent of the world’s population, are infected with the hepatitis C virus. Though it is curable, the vast majority of people living with hepatitis C reside in low- and middle-income countries where treatment is virtually inaccessible.
The main medicine used in the current standard of care—Pegylated Interferon-alfa (Peg-IFN)—can cost as much as $18,000 USD in these countries for a 48-week course of treatment. For those who cannot afford it, this price tag may mean death.
In this new report, Hepatitis C Treatment: Price, Profits, and Barriers to Access, we examine the difference in price of a 48-week course of hepatitis C treatment in low- and middle-income countries, and detail breakthroughs that have been made in countries like Egypt and Thailand to negotiate lower prices and increase access to this lifesaving medicine.
To End Hepatitis C, Patients Must Come Before Profits
Affordable access to life-saving medicines is a human right. Only when governments and pharmaceutical companies commit to making treatment available at fair prices will we close the hepatitis C treatment gap.
End the Drug War
Reframing the Blame for the War on Drugs
The war on drugs is better understood as a war on people. To stop this useless and unjust destruction, we must change how we think—and talk—about people who use drugs.
A Decade of Progress
Celebrating 10 Years of Investing in Roma Health
First established in 2008, the Roma Health Scholarships Program was intended to support young Roma trying to ensure their communities got the health care they deserved. More than a decade later, there’s no doubt it worked.